AP News January 5, 2012 on NRC’s letter to Dr. Margaret Hamburg, FDA Commissioner, on the missing data for breast implants.

Reuters, December 29, 2011. With the scandal surrounding France’s Poly Implant Prothese (PIP), questions arise whether there should be a national or worldwide breast implant registry.

Washington Post. November 19, 2011. “The science is clear: Breast cancer patients are more likely to be harmed than helped by Avastin,” said Diana Zuckerman, president of the National Research Center for Women & Families. “The risks of the drug are very substantial and can be fatal, killing patients long before they would otherwise die from the disease. FDA made a scientific decision, and it was absolutely the right decision.”

NRC President, Dr. Diana Zuckerman, tells AP about the problems with Avastin.

Reuters. August 31, 2011. U.S. health regulators said they would consider setting up a registry that tracks safety problems with breast implants, after too many patients dropped out of company-funded studies. NRC president Diana Zuckerman brings up the fact that Allergan has three times more patients participating than the other manufacturer of silicone breast implants Mentor, and that they needed to be held responsible.

Web MD. August 31, 2011. After two days of testimony on what the FDA should do about troubled long-term safety studies of silicone-gel breast implants, agency officials said the studies would continue. Public health research director of the Cancer Prevention and Treatment Fund Dana Casciotti, said the 27 page questionaires that are currently being used in the studies were too long and needed to be shortened and improved if the studies are to be effective.